Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CFO Michael Secora Sells 23,124 Shares

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CFO Michael Secora sold 23,124 shares of the business’s stock in a transaction that occurred on Wednesday, April 17th. The stock was sold at an average price of $7.58, for a total value of $175,279.92. Following the completion of the transaction, the chief financial officer now directly owns 1,231,055 shares in the company, valued at $9,331,396.90. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Michael Secora also recently made the following trade(s):

• On Wednesday, March 13th, Michael Secora sold 25,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $11.03, for a total value of $275,750.00.
• On Tuesday, February 13th, Michael Secora sold 25,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $9.86, for a total value of $246,500.00.

Recursion Pharmaceuticals Price Performance

NASDAQ RXRX opened at $7.40 on Friday. The business’s 50 day moving average price is $10.79 and its 200-day moving average price is $9.09. Recursion Pharmaceuticals, Inc. has a fifty-two week low of $4.54 and a fifty-two week high of $16.75.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its earnings results on Tuesday, February 27th. The company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.06. The firm had revenue of $10.89 million for the quarter, compared to the consensus estimate of $12.37 million. Recursion Pharmaceuticals had a negative return on equity of 72.88% and a negative net margin of 735.99%. On average, equities research analysts expect that Recursion Pharmaceuticals, Inc. will post -1.63 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. TD Cowen assumed coverage on Recursion Pharmaceuticals in a report on Friday, January 26th. They issued a “market perform” rating on the stock. KeyCorp lifted their price objective on Recursion Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a research note on Monday, March 4th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $17.00 price objective on shares of Recursion Pharmaceuticals in a research note on Tuesday, April 9th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $12.75.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Several large investors have recently modified their holdings of the stock. Ameritas Investment Partners Inc. grew its position in Recursion Pharmaceuticals by 11.1% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 11,270 shares of the company’s stock valued at $84,000 after acquiring an additional 1,129 shares during the last quarter. The Manufacturers Life Insurance Company grew its position in Recursion Pharmaceuticals by 2.7% in the 4th quarter. The Manufacturers Life Insurance Company now owns 55,778 shares of the company’s stock valued at $430,000 after acquiring an additional 1,458 shares during the last quarter. National Bank of Canada FI grew its position in Recursion Pharmaceuticals by 90.9% in the 4th quarter. National Bank of Canada FI now owns 3,150 shares of the company’s stock valued at $31,000 after acquiring an additional 1,500 shares during the last quarter. Vident Investment Advisory LLC grew its position in Recursion Pharmaceuticals by 16.6% in the 4th quarter. Vident Investment Advisory LLC now owns 13,581 shares of the company’s stock valued at $105,000 after acquiring an additional 1,934 shares during the last quarter. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its position in Recursion Pharmaceuticals by 6.2% in the 3rd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 33,002 shares of the company’s stock valued at $252,000 after acquiring an additional 1,938 shares during the last quarter. Institutional investors own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.